Trichuris suis ova - Fortress Biotech

Drug Profile

Trichuris suis ova - Fortress Biotech

Alternative Names: CNDO-201; TSO; TSO 2500; TSO 7500

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Iowa Research Foundation
  • Developer Charite of Berlin; Dr Falk Pharma; Fortress Biotech; Hadassah Medical Organization; Icahn School of Medicine at Mount Sinai; National Institutes of Health (USA); University of Wisconsin-Madison
  • Class Eukaryota; Immunotherapies; Probiotics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autistic disorder; Crohn's disease; Multiple sclerosis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 29 Jul 2016 Immanuel Krankenhaus Berlin terminates phase II TSORA trial in Rheumatoid arthritis (adjunctive therapy) in Germany (EudraCT2011-006344-71)
  • 05 May 2016 Charite University terminates phase II trial in Multiple sclerosis in Germany (EudraCT2009-015319-41)
  • 01 Feb 2016 Hadassah Medical Organization terminates a phase II trial in Autistic disorder in Israel due to lack of significant efficacy (NCT01734941)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top